GILEAD SCIENCES, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
GILEAD SCIENCES, INC. (GILD) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$541.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-24
- GILEAD SCIENCES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$541.00M, a 197.65% decline from fiscal 2024.
- GILEAD SCIENCES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $554.00M, a 765.63% increase from fiscal 2023.
- GILEAD SCIENCES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $64.00M, a 18.99% decline from fiscal 2022.
- GILEAD SCIENCES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $79.00M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$541.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $554.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $64.00M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $79.00M 10-K · filed 2024-02-23 | |
| 2014-12-31 | $9.00M 10-K · filed 2015-02-25 | |
| 2013-12-31 | $600.00K 10-K · filed 2014-02-25 | |
| 2012-12-31 | $9.00M 10-K · filed 2015-02-25 | $300.00K 10-K · filed 2013-02-27 |
| 2011-12-31 | $3.80M 10-K · filed 2014-02-25 | |
| 2010-12-31 | $11.90M 10-K · filed 2013-02-27 | |
| 2009-12-31 | -$1.10M 10-K · filed 2012-02-23 | $1.10M 10-K · filed 2011-02-28 |
| 2008-12-31 | -$23.50M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |